Inactive Instrument

Baxalta Inc Stock

Equities

US07177M1036

Pharmaceuticals

End-of-day quote Nyse Other stock markets
- ^USD	-

2016	Baxalta : Shire jumps as Vyvanse drug helps it to beat earnings forecast	RE
2016	Baxalta : Shire director pay resolution just scrapes though at general meet	RE

Latest news about Baxalta Inc

Baxalta : Shire jumps as Vyvanse drug helps it to beat earnings forecast	16-04-29	RE
Baxalta : Shire director pay resolution just scrapes though at general meet	16-04-28	RE
Baxalta : Drugmaker Shire delivers earnings beat amid deal-making push	16-02-11	RE
Baxalta : Shire says internal synergy goals from Baxalta deal higher	16-01-12	RE
Baxalta : Drugmaker Shire buys Baxalta for $32 billion after six-month pursuit	16-01-11	RE
Baxalta : Drugmaker Shire buys Baxalta for $32 billion after six-month pursuit	16-01-11	RE
Baxter : Shire, Baxalta to announce merger as soon as Monday: sources	16-01-07	RE
Shire : closer to deal to buy Baxalta - sources (Exclusive)	15-12-22	RE
Baxter : Exclusive - Shire closer to deal to buy Baxalta: sources	15-12-22	RE
Baxalta : Exclusive: Shire prepares to make new bid for Baxalta - source	15-11-24	RE
Baxalta : Shire to buy Dyax for $5.9 billion, still wants Baxalta	15-11-02	RE
Baxalta : Shire to buy Dyax for $5.9 billion, still wants Baxalta	15-11-02	RE
Baxter : to cut 1,400 jobs worldwide to boost profits	15-10-27	RE
Baxalta : Shire's eye drug data could strengthen bid for Baxalta, says CEO	15-10-27	RE
Allergan : Eye drug setback hits Shire shares amid Baxalta pursuit	15-10-19	RE

Press releases Baxalta Inc

Baxalta : Shire Completes Combination With Baxalta Creating the Global Leader in Rare Diseases and Highly Specialized Conditions	16-06-03	PR
Baxalta : CORRECTING and REPLACING Baxalta Shareholders Vote to Approve Combination	16-05-27	BU
Baxalta : OncoResponse Secures Investment from Baxalta	16-05-26	BU
Baxalta : Reports Positive Phase 1 Results for BAX 930, Investigational Recombinant ADAMTS13 to Treat Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)	16-05-25	BU
Baxalta : Thunderbolt Pharma, Inc., a Vitesse Biologics Company, Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma Inc.	16-05-24	BU

More press releases

News in other languages on Baxalta Inc

Alcoa : Wall Street termine dans le désordre une séance volatile	16-01-11
Wall Street termine dans le désordre une séance volatile	16-01-11
Baxalta : Shire met la main sur Baxalta pour 32 milliards de dollars	16-01-11
Shire : met la main sur Baxalta pour environ $32 milliards	16-01-11
Baxalta : La valeur du jour à Wall Street - BAXALTA racheté par Shire pour 32 milliards de dollars	16-01-11

Company Profile

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	-5.99%	84.46B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.85B
BIOGEN INC.	-24.88%	27.69B
UCB	+53.61%	24.28B
BIOMARIN PHARMACEUTICAL INC.	-8.08%	17.09B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-33.74%	13.67B
INCYTE CORPORATION	-16.63%	11.86B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.19%	11.79B
SWEDISH ORPHAN BIOVITRUM AB	-2.25%	8.07B

Biopharmaceuticals

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer